{"id":46125,"date":"2022-07-13T15:01:51","date_gmt":"2022-07-13T13:01:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/"},"modified":"2022-07-13T15:01:51","modified_gmt":"2022-07-13T13:01:51","slug":"beigene-appoints-chan-lee-as-general-counsel","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/","title":{"rendered":"BeiGene Appoints Chan Lee as General Counsel"},"content":{"rendered":"
\n

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE<\/a> #BTKi<\/a>–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nMr. Lee joins BeiGene from Sanofi and will bring his significant expertise leading legal functions in the biopharma industry to overseeing legal, compliance, intellectual property and related matters. Mr. Lee succeeds Scott Samuels, who built BeiGene\u2019s global legal and compliance team and served as an important part of the company\u2019s evolution to a global commercial organization.\n<\/p>\n

\n\u201cChan Lee is a proven leader in the biopharma industry and will be a valued partner to me and to our executive team. His expertise will strengthen BeiGene as we continue to expand globally and will be instrumental in advancing our business priorities,\u201d said Co-Founder, Chairman, and CEO John V. Oyler. \u201cI would also like to thank Scott Samuels for his significant contributions to BeiGene\u2019s growth over the past several years, including establishing a strong, worldwide legal function.\u201d\n<\/p>\n

\nMr. Lee most recently served as North America General Counsel and Head of Legal for Specialty Care Global Business Unit at Sanofi, responsible for the legal oversight of Sanofi\u2019s operations in the U.S. and Canada and Specialty Care business globally. Prior to Sanofi, he held roles of increasing responsibility at Pfizer, most notably as Chief Counsel for Pfizer’s Innovative Health global business. Earlier in his career, he served as Chief Counsel for the Vaccines, Oncology and Consumer Health global businesses at Pfizer, as well as Assistant General Counsel for its Asia operations.\n<\/p>\n

\n\u201cI am honored and excited to join BeiGene at this stage of growth,\u201d said Chan Lee, incoming General Counsel, BeiGene. \u201cI have admired BeiGene\u2019s vision to improve patients\u2019 lives around the world and look forward to partnering with my BeiGene colleagues across functions and regions to further advance this commitment.\u201d\n<\/p>\n

\nMr. Lee will serve on BeiGene\u2019s Executive Committee and report directly to John V. Oyler.\n<\/p>\n

\nAbout BeiGene<\/b>\n<\/p>\n

\nBeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com<\/a> and follow us on Twitter at @BeiGeneGlobal.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Chan Lee\u2019s appointment and responsibilities as General Counsel and BeiGene\u2019s plans, commitments, aspirations and goals under the heading \u201cAbout BeiGene.\u201d Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services; BeiGene\u2019s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and the impact of the COVID-19 pandemic on BeiGene\u2019s clinical development, regulatory, commercial, manufacturing, and other operations, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in BeiGene\u2019s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact<\/b>
Kevin Mannix
\n
+1 240-410-0129
\n
ir@beigene.com<\/a>\n<\/p>\n

\nMedia Contact<\/b>
Kyle Blankenship
\n
+1 667-351-5176
\n
media@beigene.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022. Mr. Lee joins … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46125","6":"format-standard","7":"category-industry"},"yoast_head":"\nBeiGene Appoints Chan Lee as General Counsel - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Appoints Chan Lee as General Counsel - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022. Mr. Lee joins ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-13T13:01:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220713005323\/en\/1512217\/21\/ChanLee.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BeiGene Appoints Chan Lee as General Counsel\",\"datePublished\":\"2022-07-13T13:01:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/\"},\"wordCount\":763,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005323\\\/en\\\/1512217\\\/21\\\/ChanLee.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/\",\"name\":\"BeiGene Appoints Chan Lee as General Counsel - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005323\\\/en\\\/1512217\\\/21\\\/ChanLee.jpg\",\"datePublished\":\"2022-07-13T13:01:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005323\\\/en\\\/1512217\\\/21\\\/ChanLee.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005323\\\/en\\\/1512217\\\/21\\\/ChanLee.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-appoints-chan-lee-as-general-counsel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Appoints Chan Lee as General Counsel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeiGene Appoints Chan Lee as General Counsel - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/","og_locale":"en_US","og_type":"article","og_title":"BeiGene Appoints Chan Lee as General Counsel - Pharma Trend","og_description":"CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022. Mr. Lee joins ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-13T13:01:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220713005323\/en\/1512217\/21\/ChanLee.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BeiGene Appoints Chan Lee as General Counsel","datePublished":"2022-07-13T13:01:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/"},"wordCount":763,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005323\/en\/1512217\/21\/ChanLee.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/","url":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/","name":"BeiGene Appoints Chan Lee as General Counsel - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005323\/en\/1512217\/21\/ChanLee.jpg","datePublished":"2022-07-13T13:01:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220713005323\/en\/1512217\/21\/ChanLee.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220713005323\/en\/1512217\/21\/ChanLee.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/beigene-appoints-chan-lee-as-general-counsel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BeiGene Appoints Chan Lee as General Counsel"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46125"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46125\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}